Movatterモバイル変換

[0]ホーム

Jump to content

Pamrevlumab

Italiano

Edit links

From Wikipedia, the free encyclopedia

Monoclonal antibody

Pharmaceutical compound

Pamrevlumab
Monoclonal antibody
Type	?
Source	Human
Target	CTGF
Clinical data
Other names	FG-3019
ATC code	none
Identifiers
CAS Number	946415-13-0
ChemSpider	none
UNII	QS5F6VTS0O
KEGG	D10969
Chemical and physical data
Formula	C₆₄₉₂H₁₀₀₁₈N₁₇₁₈O₂₀₈₆S₄₈
Molar mass	147050.38 g·mol⁻¹

Pamrevlumab (INN;^[1] development codeFG-3019) is a humanized monoclonal antibody designed for the treatment ofidiopathic pulmonary fibrosis andpancreatic cancer. It binds to theconnective tissue growth factor (CTGF) protein.^[2]

This drug was developed byFibroGen.^[3]

References

[edit]

^World Health Organization (2015)."International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113"(PDF).WHO Drug Information.29 (2).
^Sgalla G, Franciosa C, Simonetti J, Richeldi L (August 2020). "Pamrevlumab for the treatment of idiopathic pulmonary fibrosis".Expert Opinion on Investigational Drugs.29 (8):771–777.doi:10.1080/13543784.2020.1773790.PMID 32447983.S2CID 218873298.
^Statement On A Nonproprietary Name Adopted By The USAN Council - Pamrevlumab,American Medical Association.

Thismonoclonal antibody–related article is astub. You can help Wikipedia byadding missing information.

Monoclonal antibodies for theimmune system

Immune system

Human	Immunosuppression:Abrilumab Adalimumab^# Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Garadacimab Golimumab Ianalumab^† Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Nipocalimab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab^† Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation:Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other:Bertilimumab Ontamalimab Zanolimumab Combination:Nivolumab/relatlimab
Mouse	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric	Andecaliximab^† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized	Immunosuppressive:Apolizumab^§ Aselizumab Atezolizumab Benralizumab Camrelizumab^† Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab^‡ Epratuzumab Erlizumab Etrolizumab^† Fontolizumab Frexalimab^† Inebilizumab Itolizumab Lampalizumab^† Letolizumab Ligelizumab^† Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab (+hyaluronidase) Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab (+berahyaluronidase alfa) Pexelizumab Pidilizumab Plozalizumab PRO 140^† Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab^† Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412^§ Immune activation:Dostarlimab Other:Ibalizumab
Chimeric + humanized	Otelixizumab Rozanolixizumab Sutimlimab

Interleukin

Human	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab
Humanized	Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab^† Lebrikizumab Olokizumab^† Perakizumab Risankizumab Spesolimab Tildrakizumab
Veterinary	Lokivetmab

Inflammatorylesions

Mouse	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Retrieved from "https://en.wikipedia.org/w/index.php?title=Pamrevlumab&oldid=1315055160"

Categories:

Hidden categories:

[8]ページ先頭